Pathophysiological basis of migraine prophylaxis

Francesca Galletti, Letizia Maria Cupini, Ilenia Corbelli, Paolo Calabresi, Paola Sarchielli

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Several cellular and molecular mechanisms have been implicated in migraine pathophysiology including abnormal neuronal excitability and vascular events. Drugs from different pharmacological classes are used for migraine prophylaxis. These agents may normalize neuronal excitability by modulating distinct ionic channels and various neurotransmitter systems. They can also block cortical spreading depression, prevent peripheral and/or central pain sensitization, and normalize brainstem function. Most of the drugs recently used in migraine prophylaxis have been identified by serendipidy and they have been originally approved for other indications. Subsequently, their use has been extended to migraine prevention, according to their putative mechanisms of action. More recently, trials on adequate samples of migraine patients have been conducted for several drugs. In the present review, we will present and discuss the pathophysiological bases for the use of antidepressants, β-adrenergic blockers, calcium channel blockers and antiepileptic drugs in migraine prevention. Currently, the major classes of conventional migraine preventive drugs include the antidepressant amitriptyline, the β-adrenergic blocker propranolol, and the antiepileptic drugs topiramate and valproic acid. Promising results have recently been obtained for angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers. Some limited clinical findings have also been reported for atypical antipsychotic agents, nutritional supplements and also botulinum toxin. Targets of migraine preventive treatment are to reduce frequency and intensity of attacks and to decrease disability related to chronic headache.

Original languageEnglish
Pages (from-to)176-192
Number of pages17
JournalProgress in Neurobiology
Volume89
Issue number2
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Migraine Disorders
Adrenergic Antagonists
Anticonvulsants
Antidepressive Agents
Cortical Spreading Depression
Pharmaceutical Preparations
Central Nervous System Sensitization
Angiotensin II Type 1 Receptor Blockers
Headache Disorders
Amitriptyline
Botulinum Toxins
Calcium Channel Blockers
Valproic Acid
Ion Channels
Angiotensin-Converting Enzyme Inhibitors
Propranolol
Antipsychotic Agents
Brain Stem
Neurotransmitter Agents
Blood Vessels

Keywords

  • β-Adrenergic blockers
  • Antidepressants
  • Antiepileptic drugs
  • Calcium channel blockers
  • Spreading depression

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pathophysiological basis of migraine prophylaxis. / Galletti, Francesca; Cupini, Letizia Maria; Corbelli, Ilenia; Calabresi, Paolo; Sarchielli, Paola.

In: Progress in Neurobiology, Vol. 89, No. 2, 10.2009, p. 176-192.

Research output: Contribution to journalArticle

Galletti, F, Cupini, LM, Corbelli, I, Calabresi, P & Sarchielli, P 2009, 'Pathophysiological basis of migraine prophylaxis', Progress in Neurobiology, vol. 89, no. 2, pp. 176-192. https://doi.org/10.1016/j.pneurobio.2009.07.005
Galletti, Francesca ; Cupini, Letizia Maria ; Corbelli, Ilenia ; Calabresi, Paolo ; Sarchielli, Paola. / Pathophysiological basis of migraine prophylaxis. In: Progress in Neurobiology. 2009 ; Vol. 89, No. 2. pp. 176-192.
@article{315f2b9f07de47c3805e45a117558c42,
title = "Pathophysiological basis of migraine prophylaxis",
abstract = "Several cellular and molecular mechanisms have been implicated in migraine pathophysiology including abnormal neuronal excitability and vascular events. Drugs from different pharmacological classes are used for migraine prophylaxis. These agents may normalize neuronal excitability by modulating distinct ionic channels and various neurotransmitter systems. They can also block cortical spreading depression, prevent peripheral and/or central pain sensitization, and normalize brainstem function. Most of the drugs recently used in migraine prophylaxis have been identified by serendipidy and they have been originally approved for other indications. Subsequently, their use has been extended to migraine prevention, according to their putative mechanisms of action. More recently, trials on adequate samples of migraine patients have been conducted for several drugs. In the present review, we will present and discuss the pathophysiological bases for the use of antidepressants, β-adrenergic blockers, calcium channel blockers and antiepileptic drugs in migraine prevention. Currently, the major classes of conventional migraine preventive drugs include the antidepressant amitriptyline, the β-adrenergic blocker propranolol, and the antiepileptic drugs topiramate and valproic acid. Promising results have recently been obtained for angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers. Some limited clinical findings have also been reported for atypical antipsychotic agents, nutritional supplements and also botulinum toxin. Targets of migraine preventive treatment are to reduce frequency and intensity of attacks and to decrease disability related to chronic headache.",
keywords = "β-Adrenergic blockers, Antidepressants, Antiepileptic drugs, Calcium channel blockers, Spreading depression",
author = "Francesca Galletti and Cupini, {Letizia Maria} and Ilenia Corbelli and Paolo Calabresi and Paola Sarchielli",
year = "2009",
month = "10",
doi = "10.1016/j.pneurobio.2009.07.005",
language = "English",
volume = "89",
pages = "176--192",
journal = "Progress in Neurobiology",
issn = "0301-0082",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Pathophysiological basis of migraine prophylaxis

AU - Galletti, Francesca

AU - Cupini, Letizia Maria

AU - Corbelli, Ilenia

AU - Calabresi, Paolo

AU - Sarchielli, Paola

PY - 2009/10

Y1 - 2009/10

N2 - Several cellular and molecular mechanisms have been implicated in migraine pathophysiology including abnormal neuronal excitability and vascular events. Drugs from different pharmacological classes are used for migraine prophylaxis. These agents may normalize neuronal excitability by modulating distinct ionic channels and various neurotransmitter systems. They can also block cortical spreading depression, prevent peripheral and/or central pain sensitization, and normalize brainstem function. Most of the drugs recently used in migraine prophylaxis have been identified by serendipidy and they have been originally approved for other indications. Subsequently, their use has been extended to migraine prevention, according to their putative mechanisms of action. More recently, trials on adequate samples of migraine patients have been conducted for several drugs. In the present review, we will present and discuss the pathophysiological bases for the use of antidepressants, β-adrenergic blockers, calcium channel blockers and antiepileptic drugs in migraine prevention. Currently, the major classes of conventional migraine preventive drugs include the antidepressant amitriptyline, the β-adrenergic blocker propranolol, and the antiepileptic drugs topiramate and valproic acid. Promising results have recently been obtained for angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers. Some limited clinical findings have also been reported for atypical antipsychotic agents, nutritional supplements and also botulinum toxin. Targets of migraine preventive treatment are to reduce frequency and intensity of attacks and to decrease disability related to chronic headache.

AB - Several cellular and molecular mechanisms have been implicated in migraine pathophysiology including abnormal neuronal excitability and vascular events. Drugs from different pharmacological classes are used for migraine prophylaxis. These agents may normalize neuronal excitability by modulating distinct ionic channels and various neurotransmitter systems. They can also block cortical spreading depression, prevent peripheral and/or central pain sensitization, and normalize brainstem function. Most of the drugs recently used in migraine prophylaxis have been identified by serendipidy and they have been originally approved for other indications. Subsequently, their use has been extended to migraine prevention, according to their putative mechanisms of action. More recently, trials on adequate samples of migraine patients have been conducted for several drugs. In the present review, we will present and discuss the pathophysiological bases for the use of antidepressants, β-adrenergic blockers, calcium channel blockers and antiepileptic drugs in migraine prevention. Currently, the major classes of conventional migraine preventive drugs include the antidepressant amitriptyline, the β-adrenergic blocker propranolol, and the antiepileptic drugs topiramate and valproic acid. Promising results have recently been obtained for angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers. Some limited clinical findings have also been reported for atypical antipsychotic agents, nutritional supplements and also botulinum toxin. Targets of migraine preventive treatment are to reduce frequency and intensity of attacks and to decrease disability related to chronic headache.

KW - β-Adrenergic blockers

KW - Antidepressants

KW - Antiepileptic drugs

KW - Calcium channel blockers

KW - Spreading depression

UR - http://www.scopus.com/inward/record.url?scp=70249139793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249139793&partnerID=8YFLogxK

U2 - 10.1016/j.pneurobio.2009.07.005

DO - 10.1016/j.pneurobio.2009.07.005

M3 - Article

VL - 89

SP - 176

EP - 192

JO - Progress in Neurobiology

JF - Progress in Neurobiology

SN - 0301-0082

IS - 2

ER -